An essential component of type 1 diabetes mellitus is auto aggression of the immune system against insulin-secreting pancreatic cells. It is thought that early destruction of the auto aggressive mechanism prior to the complete damage of β cells should halt this process. In a 28-year-old male patient with
IntroductIon Type 1 diabetes mellitus is a meta bolic disease in which auto aggression of the immune system against pancreatic β cells is the key pathomechanism. Most of β cells had already been damaged at the time of diagnosis, but there still existed a pool of approx. 20-40% of active cells which could resume insulin produc tion provided that destruction mechanism was under control. 1 The unaffected pancreatic cells would probably secrete enough insulin to main tain plasma glucose within normal range as long as the process of auto aggression was eliminated.
Immunoablation with transplantation of auto logous hematopoietic stem cells is a medical pro cedure which stops auto aggressive immuno logical mechanisms (and the whole immune system). It has been first tested in diabetics in Brazil.
2 Fif teen patients underwent treatment with high doses of immunosuppressants and the subse quent auto logous hematopietic cell transplan tation. Longstanding independence from ex ogenous insulin with good plasma glucose con trol has been achieved in 80% of patients en rolled in the study (mean followup of 24 months,
cASE rEPort
Alleviation of exogenous insulin requirement in type 1 diabetes mellitus after immunoablation and transplantation of autologous hematopoietic stem cells a 4-week history of type 1 diabetes mellitus, three courses of plasmapheresis had been performed before cyclophosphamide, 2 g/m 2 body surface area, was administered and hematopoietic cells were obtained. Six weeks after the diagnosis, 4 doses of cyclophosphamide 50 mg/kg body weight were again administered together with antithymocyte globulin, and auto logous hematopoietic cells were transplanted. The procedure was associated with no significant side effects. Insulin requirement started to drop from the first course of plasmapheresis, and the patient has remained normoglycemic with no need of exogenous insulin or other hypoglycemic agents since the third week after the procedure, which has been 5 months until publication of this report. Independence from exogenous insulin is associated with the implemented therapy (a gradual decrease in insulin requirement has been observed after consecutive stages of the immunosuppressive treatment, with total discontinuation after bone marrow transplantation). The course of the disease and the type of treatment may suggest that such medical procedures could eliminate auto aggressive mechanism in diabetes and prevent further degeneration of insulin-producing cells, thus becoming a new therapeutic option for patients with type 1 diabetes mellitus. The insulin requirement was 0.47 IU/kg BM at the beginning of the treatment (mobiliza tion), 0.36 IU/kg BM at the day of transplanta tion, and decreased to 0.17 IU/kg BM on the en graftment day (when the granulocyte count reached >1×109/L for 3 consecutive days) (tAbLE 1). For a few weeks after engraftment the patient had received 0.11 IU/kg BM of insulin to ensure maximal protection for the rest of β cells. On day maximum followup of 48 months [Voltarelli, un published data]). There were no significant ad verse effects of the treatment (no death noted, one patient presented with pneumonia). Such positive results together with a low risk associ ated with auto logous hematopoietic cell trans plantation have prompted us to undertake a sim ilar therapy. We hereafter present the first Pol ish case of a successful type 1 diabetes mellitus treatment with auto logous hematopoietic stem cell transplantation.
KEy wordS
A 28yearold patient with a short history of type 1 diabetes mellitus was admitted to the Department of Internal Medicine, Endocrinology and Diabetol ogy of the Central Hospital of the Ministry of In terior and Administration in Warsaw. The patient presented typical diabetic symptoms: polydypsia, polyuria, weight loss of about 8 kg within 1 month, and no ketoacidosis. The auto immune pathomech anism of his diabetes had been confirmed in an tiglutamic acid decarboxylase (antiGAD) antibody testing, yielding the result of 5.41 U/mL (normal values <1.0 U/mL). On admission, his plasma glu cose was 420 mg/dL, and HbA 1c of 13.8% (HbA 1c normal range, 4.5-5.7%). The patient had been treated with intensive insulin therapy using as part and neutral protamine hagedorn insulin. Sat isfactory glucose control had been achieved grad ually. The patient was then transferred to the De partment of Hematology, Oncology and Inter nal Medicine of the Medical University of War saw for hematopoietic stem cell transplantation. The patient had no past medical history, his gen eral outcome was 0 on the WHO scale, body mass index (BMI) = 20.7 kg/m2. Plasma C peptide was confirmed before the procedure (fasting plasma C peptide was 0.3 ng/mL, and 0.6 ng/mL 1 hour after a standard meal; normal range: 1.77-4.68 ng/mL). In HLA testing, DRB1 04, 07; DQB1 0304, 0202 were found, one of which (DRB1 04) is more often observed in type 1 diabetes mellitus.
3 The study was approved by the Bioethics Committee of the Med ical University of Warsaw. After giving his written, informed consent, the patient was qualified for im munoablation followed by auto logous hematopoi etic stem cell transplantation. Before that, on April 9-12, 2008, three courses of plasmapheresis had been performed to immediately decrease the pa tient's antiβ cell antibody titer. 4
Hematopoietic stem cell mobilization From April 14, 2008, the patient had received 2 g/m2 in the early phase of type 1 diabetes mellitus following immunosuppressive treatment and the subsequent auto logous hematopoietic stem cell transplantation. The method involved de struction of the patient's immune system and also the auto immune process which is the main path omechanism in type 1 diabetes mellitus. From the theoretical point of view (it has not been con firmed empirically yet), this method of treatment could only be successful in patients with a short history of the disease, when there are at least some β cells still functioning. As soon as the auto aggressive mechanism is stopped, pancreatic cells might be able to resume secretion of sufficient amounts of insulin to maintain normal glucose level. The patient must fulfill two conditions to be scheduled for transplantation in accordance with our medical protocol: 1 C peptide positive plasma to confirm that en dogenous insulin secretion is preserved 2 auto immune basis of the disease (antibody testing, e.g. antiGAD). In our case, the course of the implemented treatment has confirmed what had previously been achieved in Brazil 2 ; at the same time it has been the first case described by other authors. At this point in time (several patients have un dergone the therapy so far), it is hard to say how long the achieved result will be maintained. Sev eral factors other than efficacy of the procedure may play an important role here, e.g. the num ber of remaining β cells after treatment (which depends on the time of the diagnosis: the later the diagnosis is made, the fewer the cells will be present), to what degree the patient follows life style recommendations after the procedure (be ing overweight, risk for type 2 diabetes mellitus) and the chance of recurrent auto immune disor der. The currently available data (very scarce un til now) suggest that the recurrence rate is about 20%, and it is estimated on the basis of the Brazil ian data and other studies concerning auto logous BMT in different auto immune diseases.
6
This results from the fact that constraining stem cells to recreate the immune system does not eliminate the patient's genetic susceptibility to diabetes. Genetic predisposition is responsi ble only for the risk of developing type 1 diabetes mellitus and the health risk in siblings is 27.3% in monozygotic twins.
5 This means that the re maining 70% of the risk is related to abnormal ities in individual development of the immune system after birth.
The risk of death is the most serious complica tion of transplantation. It is relatively low in auto logous BMT. Autotransplantations have routinely been performed in patients aged <70 years with a spectrum of different diseases, and in multiple sclerosis patients, who constitute a group most similar in terms of demographics to type 1 diabe tes mellitus, the risk of death on transplantation is close to 0%; since 2000, no cases of death as sociated with the procedure have been recorded in Europe (n = 63).
6 It will be possible to estimate 24 after transplantation (June 30, 2008) exoge nous insulin treatment was discontinued. During the following days fasting plasma glucose was nor mal, but a few episodes of hyperglycemia were ob served, with maximal plasma glucose of 125 mg/dL (May 25, 2008) . Plasma C peptide levels measured in fasting state and 1 hour after a standard meal were 0.3 ng/mL and 0.6 ng/mL, respectively, (nor mal range: 1.77-4.68 ng/mL) on diagnosis, 1.15 ng/mL and 3.05 ng/mL before transplantation, 1.0 ng/mL and 2.0 ng/mL after insulin treatment withdrawal, and 2.99 ng/mL and 4.14 ng/mL 3 months after bone marrow transplantation (BMT). Three months after transplantation HbA 1c was of 5.2% (tAbLE 1) . On discharge, continuation of di abetic diet was recommended due to a possible ex cretory dysfunction of pancreatic β cells. Five months has passed since transplantation at the time of submitting the paper for publica tion, and the patient is in no need of exogenous insulin intake; his plasma glucose remains within normal range. We have not tried any oral antidia betic drugs stimulating insulin secretion or drugs inhibiting insulin resistance (BMI 20.7 kg/m2). continuous glucose monitoring system On Sep tember [26] [27] [28] 2008 , plasma glucose monitor ing using continuous glucose monitoring sys tem (CGMS) was performed. Mean glucose level was 94 mg/dL (minimal 53, maximal 152 mg/dL) in 72hour monitoring. Minimum and maximum plasma glucose levels were measured immediately after the system was connected. For the remaining monitoring time (99% of the time) glucose level stayed within normal limits and mean plasma glu cose was 94 mg/dL (minimum -76 mg/dL, max imum -133 mg/dL). The FIGurE presents 24hour glucose level record. dIScuSSIon The present case has been the first successful Polish attempt to achieve remission 21:00 0:00 3:00 6:00 9:00
FIGurE 24-hour registration of the patient's plasma glucose is possible to achieve satisfactory results as long as the patient follows a diabetic diet. If the further course of disease in the described patient leads to stable independence from ex ogenous insulin, and if similar results are ob tained in other patients, the procedure will be come a new therapeutic method for early diag nosed type 1 diabetes mellitus. It is not unlikely that immunoablative treatment alone (without transplantation) could have similar results, but the methodo logical scheme described above was based on the data from the Brazilian center; only plasmapheresis was added according to the rec ommendations of other authors. Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and ado-7 lescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008; 9: 197-201. Abdul-Rasoul M, Habib H, Al-Khouly M. ‚The honeymoon phase' in chil-8 dren with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006; 7: 101-107. the actual rate of complications following auto logous stem cell transplantation in type 1 dia betes mellitus when such procedures are per formed in a larger number of patients. To date, no death has been reported (in the data published by the Brazilian group), which however does not exclude such a risk. In each patient the danger of possible postprocedural complications al ways has to be confronted with the risk of major complications of type 1 diabetes mellitus such as hypo and hyperglycemia, potentially severe or gan and vascular complications, and premature death. Although auto logous stem cell transplan tation could lead to severe complications, it can be a medical alternative for patients with a short history of type 1 diabetes mellitus.
Our patient is another one (at least the 19th in cluding all those who had transplantations done in Brazil [Voltarelli, unpublished data] ) to have achieved remission of type 1 diabetes mellitus af ter the treatment. We sometimes observe sponta neous remission in patients with type 1 diabetes 7,8 , but it happens rather rarely and lasts for a limit ed period of time. In a group of patients that had been excluded from our experiment, we did not note any case of a spontaneous remission. Fur thermore, the current study showed a strong re lationship between a decrease in exogenous in sulin requirement and the immunosuppressive treatment in our patient. However, the great est change in insulin requirement occurred after BMT -it dropped from 26 to 12 units within 6 days. Moreover, after upper respiratory tract in fections no recurrence of diabetes was observed, which is usually not the case in spontaneous re mission (IVGTT and CGMS results after infec tions). This could further confirm that elimination of the auto aggressive process prolongs the peri od of remission.
IVGTT demonstrated that the first phase of in sulin secretion was not restored after treatment while the second phase was preserved. It is an ex pected result, because decreased insulin secre tion in the first phase is the first meta bolic dis turbance in natural history of type 1 diabetes mellitus, confirming dysfunction of pancreat ic β cells which occurs before clinical symptoms appear. We do not expect our patient to immedi ately regenerate the lost β cells since at the time of diagnosis as much as 60 -80% of his β cells had been destroyed. What we are hoping for instead is to maintain the patient's plasma glucose with in normal range due to the activity of the remain ing cells. CGMS and selfcontrol results, as well as the documented HbA 1c , show that even though the first phase of insulin secretion is impaired, it Uniezależnienie się od egzogennej insuliny w cukrzycy typu 1 po immunoablacji i przeszczepieniu własnych komórek krwiotwórczych
